Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes
Marilyne Jarjour(Montreal Heart Institute), Anique Ducharme(Montreal Heart Institute), Mark Liszkowski(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Michel White(Montreal Heart Institute), Annik Fortier(Montreal Heart Institute), Geneviève Giraldeau(Montreal Heart Institute), Simon de Denus(Montreal Heart Institute), Patrick Garceau(Montreal Heart Institute), Nadia Bouabdallaoui(Montreal Heart Institute), Marie-Claude Parent(Montreal Heart Institute), Jacinthe Leclerc, Charaf E Ahnadi(Université de Sherbrooke), Jean‐Lucien Rouleau(Montreal Heart Institute), Serge Lepage, Denis Brouillette(Montreal Heart Institute), Maxime Tremblay‐Gravel(Montreal Heart Institute)
Cited by 12
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
|New England Journal of Medicine|2004|1.9k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k